+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Proteinuria Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023 - Product Image

Proteinuria Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023

  • ID: 4849314
  • Report
  • October 2019
  • Region: Global
  • 153 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global Proteinuria Therapeutics Market: About this market
The proteinuria therapeutics market analysis considers sales from ACE inhibitors, ARBs, and other therapeutic products. Our analysis also considers the sales of proteinuria therapeutics in Asia, Europe, North America, and ROW. In 2018, the ACE inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the prevention of an enzyme in the body from producing angiotensin II, which narrows the blood vessels will play a significant role in the ACE inhibitors segment to maintain its market position. Also, our global proteinuria therapeutics market report looks at factors such as recent approvals and launch of advanced urinalysis diagnostic kits, increasing prevalence of associated risk factors, and growing geriatric population. However, lack of curative therapies, adverse effects of available therapeutics, and stringent regulations may hamper the growth of the proteinuria therapeutics industry over the forecast period.

Global Proteinuria Therapeutics Market: Overview

Increasing prevalence of associated risk factors
Proteinuria is a condition in which urine contains an abnormal amount of protein. This condition can be a sign of damage within the kidneys and CKD: the latter can result from diabetes as well as high blood pressure hypertension. Proteinuria can be caused by diseases that do not involve the kidneys, such as multiple myeloma and others, such as, AIDS, lupus, and rheumatoid arthritis, which also cause inflammation in the kidneys. Globally, the prevalence of all these diseases and infections is very high and is increasing continuously. This multifactorial etiology of the condition increases the demand for treatment options and, thus, drives the growth of the market at a CAGR of almost 3% during the forecast period.

Introduction of smartphone-based diagnosis and treatment
Advances in technology help in increasing the adherence of patients to treatment and, thus, obtain effective and quick results. They help in improving the condition of patients in less time. With the recent advances in technology and the proliferation of smartphone-based applications: urinalysis is also providing effective and quick results at a lower cost. Smartphone-based applications are unique as they are autonomous and do not need a specialist to make clinical decisions. Also, changing lifestyles and technological developments are encouraging more people to opt for application-based treatment due to its easy access. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of several major players, the global proteinuria therapeutics market is moderately fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proteinuria therapeutics manufacturers, that include AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.

Also, the proteinuria therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • ACE inhibitors - Market size and forecast 2018-2023
  • ARBs - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Introduction of smartphone-based diagnosis and treatment.
  • Advent of novel therapies
  • Increasing awareness about renal disorders
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: ACE inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: ACE inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 22: ARBs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: ARBs - Year-over-year growth 2019-2023 (%)
Exhibit 24: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Proportion of geriatric population in Asia 2009 and 2018 (% of the total population)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Prevalence/incidence of associated risk factors of proteinuria
Exhibit 46: Growth of geriatric population 2009-2018 (%)
Exhibit 47: Side effects of ACE inhibitors used for the treatment of proteinuria
Exhibit 48: Impact of drivers and challenges
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: AbbVie Inc. - Vendor overview
Exhibit 55: AbbVie Inc. - Business segments
Exhibit 56: AbbVie Inc. - Organizational developments
Exhibit 57: AbbVie Inc. - Geographic focus
Exhibit 58: AbbVie Inc. - Key offerings
Exhibit 59: AbbVie Inc. - Key customers
Exhibit 60: AstraZeneca Plc - Vendor overview
Exhibit 61: AstraZeneca Plc - Business segments
Exhibit 62: AstraZeneca Plc - Organizational developments
Exhibit 63: AstraZeneca Plc - Geographic focus
Exhibit 64: AstraZeneca Plc - Key offerings
Exhibit 65: AstraZeneca Plc - Key customers
Exhibit 66: Boehringer Ingelheim International GmbH - Vendor overview
Exhibit 67: Boehringer Ingelheim International GmbH - Business segments
Exhibit 68: Boehringer Ingelheim International GmbH - Organizational developments
Exhibit 69: Boehringer Ingelheim International GmbH - Geographic focus
Exhibit 70: Boehringer Ingelheim International GmbH - Segment focus
Exhibit 71: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 72: Boehringer Ingelheim International GmbH - Key customers
Exhibit 73: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 74: Bristol-Myers Squibb Co. - Business segments
Exhibit 75: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 76: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 77: Bristol-Myers Squibb Co. - Key offerings
Exhibit 78: Bristol-Myers Squibb Co. - Key customers
Exhibit 79: Merck & Co. Inc. - Vendor overview
Exhibit 80: Merck & Co. Inc. - Business segments
Exhibit 81: Merck & Co. Inc. - Organizational developments
Exhibit 82: Merck & Co. Inc. - Geographic focus
Exhibit 83: Merck & Co. Inc. - Segment focus
Exhibit 84: Merck & Co. Inc. - Key offerings
Exhibit 85: Merck & Co. Inc. - Key customers
Exhibit 86: Novartis AG - Vendor overview
Exhibit 87: Novartis AG - Business segments
Exhibit 88: Novartis AG - Organizational developments
Exhibit 89: Novartis AG - Geographic focus
Exhibit 90: Novartis AG - Segment focus
Exhibit 91: Novartis AG - Key offerings
Exhibit 92: Novartis AG - Key customers
Exhibit 93: Pfizer Inc. - Vendor overview
Exhibit 94: Pfizer Inc. - Business segments
Exhibit 95: Pfizer Inc. - Organizational developments
Exhibit 96: Pfizer Inc. - Geographic focus
Exhibit 97: Pfizer Inc. - Segment focus
Exhibit 98: Pfizer Inc. - Key offerings
Exhibit 99: Pfizer Inc. - Key customers
Exhibit 100: Sanofi - Vendor overview
Exhibit 101: Sanofi - Business segments
Exhibit 102: Sanofi - Organizational developments
Exhibit 103: Sanofi - Geographic focus
Exhibit 104: Sanofi - Segment focus
Exhibit 105: Sanofi - Key offerings
Exhibit 106: Sanofi - Key customers
Exhibit 107: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 108: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 115: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 116: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 117: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 118: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 119: Validation techniques employed for market sizing
Exhibit 120: Definition of market positioning of vendors

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global proteinuria therapeutics market: AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the introduction of smartphone-based diagnosis and treatment.”

According to the report, one of the major drivers for this market is the increasing prevalence of associated risk factors.

Further, the report states that one of the major factors hindering the growth of this market is the lack of curative therapies.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll